Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy ...

The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.

The latest OXB agreement will help advance the company’s CAR-T therapies and provide a “reliable, scalable manufacturing ...

Ahead of the readouts, BMS and J&J have started an educational push called “Change the Target. Change What’s Possible,” they announced Tuesday. The campaign is designed to inform clinicians who manage ...

Just in time for the annual American Society of Clinical Oncology (ASCO) meeting in Chicago, Bristol Myers Squibb launched a campaign to highlight its progress in dual immuno-oncology (I-O) research ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for approximately ...

BMY Q4 2025 earnings call recap: growth portfolio momentum, pipeline catalysts, 2026 guidance, and Eliquis LOE risks.

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people ...

Huzhou FFD Power will localize BMS, EMS, and C&I BESS cabinet production in Europe; initial cabinet platforms: 261 ...